Verastem | VSTM - Current Liabilities


Verastem reported $66.84M in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
AbbVie USD 41.64B 458M Jun/2026
Alaunos Therapeutics USD 595K 218K Mar/2026
AstraZeneca USD 31.55B 1.02B Jun/2026
Curis USD 14.97M 898K Mar/2026
Cytokinetics USD 181.43M 17.76M Jun/2026
Gilead Sciences USD 11.02B 1.54B Jun/2026
Incyte USD 1.31B 177.55M Jun/2026
Laboratory Of America USD 2.12B 516.4M Jun/2026
Novartis USD 31.75B 374M Jun/2026
Pfizer USD 32.65B 1.7B Jun/2026
Roche Holding CHF 28.85B 846M Jun/2026
TG Therapeutics USD 268.49M 81.38M Jun/2026
Verastem USD 66.84M 5.42M Mar/2026